Idenix Pharmaceuticals, Inc. – Amendment No. 4 to Development, License and Commercialization Agreement Idenix Pharmaceuticals, Inc. Idenix (Cayman) Limited Novartis Pharma Ag (November 8th, 2007)
This Amendment No. 4 (Amendment No. 4) to the Development, License and Commercialization Agreement is made as of 28 September 2007 (Amendment Signing Date) between Idenix Pharmaceuticals, Inc. of 60 Hampshire Street, Cambridge, Massachusetts 02139, USA (Idenix U.S.), Idenix (Cayman) Limited c/o Walkers SPV Limited, Walker House, Mary Street, George Town, Grand Cayman, Cayman Islands (Idenix Cayman and, together with Idenix U.S., Idenix), and Novartis Pharma AG of Forum 1, Novartis Campus, 4056 Basel, Switzerland (Novartis).
Idenix Pharmaceuticals, Inc. – Contract (March 16th, 2006)
Idenix Pharmaceuticals, Inc. – Contract (December 15th, 2003)
Exhibit 10.28 Idenix Pharmaceuticals, Inc. 125 CambridgePark Drive Cambridge, Massachusetts 02140 March 21, 2003 Novartis Pharma AG Lichtstrasse 35 CH-4002 Basel Switzerland Attention: Thomas Ebeling Chief Executive Officer Gentlemen: We refer to the Stock Purchase Agreement (the "Agreement"), dated as of the date hereof, by and among Idenix Pharmaceuticals, Inc. ("Idenix"), the Sellers (as defined therein) and Novartis Pharma AG ("Novartis"). Unless otherwise indicated herein, capitalized terms used but not defined herein shall have the respective meanings assigned to such terms in the Agreement. As a material inducement to, and in consideration of, Novartis's execution and delivery of the Agreement, Idenix covenants and agrees that, from and after the Closing Date until the earlier to occur of (x) such time that Novartis and its Affiliates own less that 35% of the Voting Stock (as de